Macro- or microencapsulation of pig islets to cure type 1 diabetes
Macro- or microencapsulation of pig islets to cure type 1 diabetes
复制标题
DOI：
10.3748/wjg.v18.i47.6885
复制
发表时间：
2012-12-21
影响因子：
4.3
通讯作者：
Gianello, Pierre
中科院分区：
文献类型：
--
作者：
Dufrane, Denis;Gianello, Pierre
Although allogeneic islet transplantation can successfully cure type 1 diabetes, it has limited applicability. For example, organs are in short supply; several human pancreas donors are often needed to treat one diabetic recipient; the intrahepatic site may not be the most appropriate site for islet implantation; and immunosuppressive regimens, which are associated with side effects, are often required to prolong survival of the islet graft. An alternative source of insulin-producing cells would therefore be of major interest. Pigs represent a possible alternative source of beta cells. Grafting of pig islets may appear difficult because of the immunologic species barrier, but pig islets have been shown to function in primates for at least 6 mo with clinically incompatible immunosuppression. Therefore, a bioartificial pancreas made of encapsulated pig islets may resolve issues associated with islet allotransplantation. Although several groups have shown that encapsulated pig islets are functional in small-animal models, less is known about the use of bioartificial pancreases in large-animal models. In this review, we summarize current knowledge of encapsulated pig islets, to determine obstacles to implantation in humans and possible solutions to overcome these obstacles. (C) 2012 Baishideng. All rights reserved.
